» Articles » PMID: 36672317

Prognostic Value of CD8+ Lymphocytes in Hepatocellular Carcinoma and Perineoplastic Parenchyma Assessed by Interface Density Profiles in Liver Resection Samples

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Jan 21
PMID 36672317
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) often emerges in the setting of long-standing inflammatory liver disease. CD8 lymphocytes are involved in both the antitumoral response and hepatocyte damage in the remaining parenchyma. We investigated the dual role of CD8 lymphocytes by assessing density profiles at the interfaces of both HCC and perineoplastic liver parenchyma with surrounding stroma in whole-slide immunohistochemistry images of surgical resection samples. We applied a hexagonal grid-based digital image analysis method to sample the interface zones and compute the CD8 density profiles within them. The prognostic value of the indicators was explored in the context of clinicopathological, peripheral blood testing, and surgery data. Independent predictors of worse OS were a low standard deviation of CD8+ density along the tumor edge, high mean CD8+ density within the epithelial aspect of the perineoplastic liver-stroma interface, longer duration of surgery, a higher level of aspartate transaminase (AST), and a higher basophil count in the peripheral blood. A combined score, derived from these five independent predictors, enabled risk stratification of the patients into three prognostic categories with a 5-year OS probability of 76%, 40%, and 8%. Independent predictors of longer RFS were stage pT1, shorter duration of surgery, larger tumor size, wider tumor-free margin, and higher mean CD8+ density in the epithelial aspect of the tumor-stroma interface. We conclude that (1) our computational models reveal independent and opposite prognostic impacts of CD8+ cell densities at the interfaces of the malignant and non-malignant epithelium interfaces with the surrounding stroma; and (2) together with pathology, surgery, and laboratory data, comprehensive prognostic models can be constructed to predict patient outcomes after liver resection due to HCC.

Citing Articles

Significance of Immune and Non-Immune Cell Stroma as a Microenvironment of Hepatocellular Carcinoma-From Inflammation to Hepatocellular Carcinoma Progression.

Baj J, Kolodziej M, Kobak J, Januszewski J, Syty K, Portincasa P Int J Mol Sci. 2024; 25(19).

PMID: 39408564 PMC: 11475949. DOI: 10.3390/ijms251910233.


Low CD8+ Density Variation and R1 Surgical Margin as Independent Predictors of Early Post-Resection Recurrence in HCC Patients Meeting Milan Criteria.

Stulpinas R, Jakiunaite I, Sidabraite A, Rasmusson A, Zilenaite-Petrulaitiene D, Strupas K Curr Oncol. 2024; 31(9):5344-5353.

PMID: 39330022 PMC: 11431076. DOI: 10.3390/curroncol31090394.


Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances.

Wang X, Yuan Z, Li Z, He X, Zhang Y, Wang X Front Immunol. 2024; 15:1354313.

PMID: 38426090 PMC: 10902128. DOI: 10.3389/fimmu.2024.1354313.


The molecular mechanism of actions and clinical utilities of tumor infiltrating lymphocytes in gastrointestinal cancers: a comprehensive review and future prospects toward personalized medicine.

Piroozkhah M, Gholinezhad Y, Piroozkhah M, Shams E, Nazemalhosseini-Mojarad E Front Immunol. 2023; 14:1298891.

PMID: 38077386 PMC: 10704251. DOI: 10.3389/fimmu.2023.1298891.

References
1.
Rushing C, Bulusu A, Hurwitz H, Nixon A, Pang H . A leave-one-out cross-validation SAS macro for the identification of markers associated with survival. Comput Biol Med. 2015; 57:123-9. PMC: 4306627. DOI: 10.1016/j.compbiomed.2014.11.015. View

2.
He Y, Liang T, Mo S, Chen Z, Zhao S, Zhou X . Effect of timing of surgical resection of primary hepatocellular carcinoma on survival outcomes in elderly patients and prediction of clinical models. BMC Gastroenterol. 2021; 21(1):230. PMC: 8139139. DOI: 10.1186/s12876-021-01815-4. View

3.
Nam D, Chapiro J, Paradis V, Seraphin T, Kather J . Artificial intelligence in liver diseases: Improving diagnostics, prognostics and response prediction. JHEP Rep. 2022; 4(4):100443. PMC: 8867112. DOI: 10.1016/j.jhepr.2022.100443. View

4.
Nault J, Galle P, Marquardt J . The role of molecular enrichment on future therapies in hepatocellular carcinoma. J Hepatol. 2018; 69(1):237-247. DOI: 10.1016/j.jhep.2018.02.016. View

5.
Villa E, Colantoni A, Camma C, Grottola A, Buttafoco P, Gelmini R . Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems. J Clin Oncol. 2003; 21(3):441-6. DOI: 10.1200/JCO.2003.11.051. View